Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…

Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.

Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on…